{
    "clinical_study": {
        "@rank": "97585", 
        "acronym": "YKP", 
        "arm_group": [
            {
                "arm_group_label": "YKP10811 placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo"
            }, 
            {
                "arm_group_label": "YKP10811 10mg", 
                "arm_group_type": "Experimental", 
                "description": "YKP10811 10mg"
            }, 
            {
                "arm_group_label": "YKP10811 20mg", 
                "arm_group_type": "Experimental", 
                "description": "YKP10811 20mg"
            }, 
            {
                "arm_group_label": "YKP10811 40mg", 
                "arm_group_type": "Experimental", 
                "description": "YKP10811 40mg"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is to investigate efficacy and safety of YKP10811 in Subjects With Irritable\n      Bowel Syndrome With Constipation. The difference of responder rate between test group (10,\n      20 and 40mg) and placebo will be evaluated."
        }, 
        "brief_title": "Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Irritable Bowel Syndrome", 
            "Constipation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Constipation", 
                "Irritable Bowel Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. more than 18 years old\n\n          2. patients met with ROME III criteria for C-type IBS\n\n        Exclusion Criteria:\n\n          -  pregnancy or lactation\n\n          -  a history of surgery for gastrointestinal tract\n\n          -  a history of gestrointestinal bleeding, diverticulitis and ileus within 1 year of\n             screening visit\n\n          -  inflammatory bowel disease or malignant tumor within 5 years of screening visit\n\n          -  taking drugs that could have impact on efficacy assessment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "276", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02082457", 
            "org_study_id": "YKP10811"
        }, 
        "intervention": {
            "arm_group_label": [
                "YKP10811 placebo", 
                "YKP10811 10mg", 
                "YKP10811 20mg", 
                "YKP10811 40mg"
            ], 
            "description": "YKP10811 10mg , 20mg, 40mg or placebo administered orally once a day during 12 weeks", 
            "intervention_name": "YKP10811 10mg , 20mg, 40mg and placebo", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Irritable Bowel Syndrome", 
            "Constipation", 
            "C-IBS", 
            "YKP", 
            "Multi-center", 
            "Randomized", 
            "Double blinded", 
            "Placebo-controlled", 
            "Phase II trial"
        ], 
        "lastchanged_date": "March 7, 2014", 
        "location": {
            "contact": {
                "last_name": "Hyojin Park, MD.PhD.", 
                "phone": "82-2-2008-2129"
            }, 
            "facility": {
                "address": {
                    "city": "Gang nam Gu", 
                    "country": "Korea, Republic of", 
                    "state": "Seoul", 
                    "zip": "135-720"
                }, 
                "name": "Gang Nam Severance Hospital"
            }, 
            "investigator": {
                "last_name": "Hyo jin Park, MD.PhD.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "Multi-center, Randomized, Double Blinded, Placebo-controlled, Phase II Trial to Assess the Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation", 
        "overall_contact": {
            "email": "seobj@sk.com", 
            "last_name": "Beom jun Seo, manager", 
            "phone": "82-2-2008-2129"
        }, 
        "overall_official": {
            "affiliation": "Gangnam Severance Hospital", 
            "last_name": "Hyo jin Park, professional", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ministry of Food and Drug Safety : South Korea", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "an improvement of equl and more than 30% from baseline in the average of the daily worst abdominal pain score and an increase of equal and more than 1 CSBM from baseline", 
            "measure": "Abdominal pain intensity & stool frequency responder", 
            "safety_issue": "No", 
            "time_frame": "12weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02082457"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "the dgree of symptom relief on abdominal pain, bloating, stool frequency, stool consitency, etc.", 
            "measure": "subject global assessment", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "SK Chemicals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "SK Chemicals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}